Pathos AI, Inc. has closed $237 million in Series E financing, led by Bristol Myers Squibb, to scale their AI-driven drug development platform and advance their oncology pipeline.
Amount Raised
$237 Million
Round Type
Series E
ChicagoBiotechnologyHealth CareArtificial IntelligenceTherapeuticsMachine LearningPharmaceuticalHealth DiagnosticsInvestors
Description
Pathos AI, Inc., a clinical-stage AI and technology company, has successfully secured $237 million in a Series E financing round. This funding will help scale their Agentic AI drug development platform and advance their oncology pipeline. The post-money valuation of the company is approximately $3 billion. The financing was supported by existing investors and led by Bristol Myers Squibb.
Quick answer
Pathos AI raised $237 Million in a Series E round, dated October 23, 2026. Investors: Bristol Myers Squibb. Pathos AI is based in Chicago, Illinois, United States.
- How much did Pathos AI raise?
- Pathos AI raised $237 Million in a Series E round on October 23, 2026.
- Who invested in Pathos AI?
- Bristol Myers Squibb is named as investors in this round.
- What does Pathos AI do?
- Pathos is an AI-enabled biotechnology company focused on re-engineering drug development, leveraging the power of technology to bring precision medicine to patients through partnerships with pharmaceutical companies.
- Where is Pathos AI based and how big is it?
- Pathos AI is based in Chicago, Illinois, United States. Fundz records about 98 employees.
- Who are the decision-makers at Pathos AI?
- Fundz holds 1 contact at Pathos AI. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Pharmaceutical around the same time
Companies in the same sectors as Pathos AI that raised within 45 days of this round, from Fundz verified event records.
- Alterra Labs raised $13M (Seed) on November 10, 2026.
- Laza Medical raised $160M (Series B) on November 4, 2026.
- Recursion Pharmaceuticals raised $200M (Post-IPO Equity) on October 15, 2026.
- AIBORN Ltd raised an undisclosed amount on October 5, 2026.
- UltraSight raised $24M (Series B) on September 23, 2026.
- Cascader raised an undisclosed amount (Seed) on September 23, 2026.
Who to call at Pathos AI, and when
A new round usually means Pathos AI is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Pathos AI raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Pathos AI, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Pathos AI. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Pathos AI raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Pathos AI raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.